TY - JOUR
T1 - Early Outcomes of Adult Heart Transplantation From COVID-19 Infected Donors
AU - Madan, Shivank
AU - Chan, Marvyn Allen G.
AU - Saeed, Omar
AU - Hemmige, Vagish
AU - Sims, Daniel B.
AU - Forest, Stephen J.
AU - Goldstein, Daniel J.
AU - Patel, Snehal R.
AU - Jorde, Ulrich P.
N1 - Publisher Copyright:
© 2023 American College of Cardiology Foundation
PY - 2023/6/20
Y1 - 2023/6/20
N2 - Background: There is a paucity of data on heart transplantation (HT) using COVID-19 donors. Objectives: This study investigated COVID-19 donor use, donor and recipient characteristics, and early post-HT outcomes. Methods: Between May 2020 and June 2022, study investigators identified 27,862 donors in the United Network for Organ Sharing, with 60,699 COVID-19 nucleic acid amplification testing (NAT) performed before procurement and with available organ disposition. Donors were considered “COVID-19 donors” if they were NAT positive at any time during terminal hospitalization. These donors were subclassified as “active COVID-19” (aCOV) donors if they were NAT positive within 2 days of organ procurement, or “recently resolved COVID-19” (rrCOV) donors if they were NAT positive initially but became NAT negative before procurement. Donors with NAT-positive status >2 days before procurement were considered aCOV unless there was evidence of a subsequent NAT-negative result ≥48 hours after the last NAT-positive result. HT outcomes were compared. Results: During the study period, 1,445 “COVID-19 donors” (COVID-19 NAT positive) were identified; 1,017 of these were aCOV, and 428 were rrCOV. Overall, 309 HTs used COVID-19 donors, and 239 adult HTs from COVID-19 donors (150 aCOV, 89 rrCOV) met study criteria. Compared with non-COV, COVID-19 donors used for adult HT were younger and mostly male (∼80%). Compared with HTs from non-COV donors, recipients of HTs from aCOV donors had increased mortality at 6 months (Cox HR: 1.74; 95% CI: 1.02-2.96; P = 0.043) and 1 year (Cox HR: 1.98; 95% CI: 1.22-3.22; P = 0.006). Recipients of HTs from rrCOV and non-COV donors had similar 6-month and 1-year mortality. Results were similar in propensity-matched cohorts. Conclusions: In this early analysis, although HTs from aCOV donors had increased mortality at 6 months and 1 year, HTs from rrCOV donors had survival similar to that seen in recipients of HTs from non-COV donors. Continued evaluation and a more nuanced approach to this donor pool are needed.
AB - Background: There is a paucity of data on heart transplantation (HT) using COVID-19 donors. Objectives: This study investigated COVID-19 donor use, donor and recipient characteristics, and early post-HT outcomes. Methods: Between May 2020 and June 2022, study investigators identified 27,862 donors in the United Network for Organ Sharing, with 60,699 COVID-19 nucleic acid amplification testing (NAT) performed before procurement and with available organ disposition. Donors were considered “COVID-19 donors” if they were NAT positive at any time during terminal hospitalization. These donors were subclassified as “active COVID-19” (aCOV) donors if they were NAT positive within 2 days of organ procurement, or “recently resolved COVID-19” (rrCOV) donors if they were NAT positive initially but became NAT negative before procurement. Donors with NAT-positive status >2 days before procurement were considered aCOV unless there was evidence of a subsequent NAT-negative result ≥48 hours after the last NAT-positive result. HT outcomes were compared. Results: During the study period, 1,445 “COVID-19 donors” (COVID-19 NAT positive) were identified; 1,017 of these were aCOV, and 428 were rrCOV. Overall, 309 HTs used COVID-19 donors, and 239 adult HTs from COVID-19 donors (150 aCOV, 89 rrCOV) met study criteria. Compared with non-COV, COVID-19 donors used for adult HT were younger and mostly male (∼80%). Compared with HTs from non-COV donors, recipients of HTs from aCOV donors had increased mortality at 6 months (Cox HR: 1.74; 95% CI: 1.02-2.96; P = 0.043) and 1 year (Cox HR: 1.98; 95% CI: 1.22-3.22; P = 0.006). Recipients of HTs from rrCOV and non-COV donors had similar 6-month and 1-year mortality. Results were similar in propensity-matched cohorts. Conclusions: In this early analysis, although HTs from aCOV donors had increased mortality at 6 months and 1 year, HTs from rrCOV donors had survival similar to that seen in recipients of HTs from non-COV donors. Continued evaluation and a more nuanced approach to this donor pool are needed.
KW - COVID-19 donors
KW - donor characteristics
KW - heart transplantation
KW - transplant outcomes
UR - http://www.scopus.com/inward/record.url?scp=85160764033&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85160764033&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2023.04.022
DO - 10.1016/j.jacc.2023.04.022
M3 - Article
C2 - 37204379
AN - SCOPUS:85160764033
SN - 0735-1097
VL - 81
SP - 2344
EP - 2357
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 24
ER -